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Abstract 
Androgens and the androgen receptor (AR) are essential for growth and differentiation of the 
normal prostate gland as well as proliferation and survival of prostate cancer (PCa). Increasing 
evidence suggests that reactivation of the AR plays a pivotal role in disease progression to cas-
tration-resistant PCa (CRPC). Forkhead box (FOX) factors exert two distinct effects on AR 
function in PCa. The A-class of FOX proteins, especially FOXA1, functions as a pioneer factor to 
facilitate AR transactivation and PCa growth. In contrast, the O-class of FOX proteins such as 
FOXO1 and FOXO3, which are downstream effectors of the PTEN tumor suppressor, inhibit the 
transcriptional activity of either full-length AR or constitutively active splice variants of AR in a 
direct or indirect manner in PCa. FOXO1 also contributes to taxane-mediated inhibition of the AR 
and CRPC growth. Therefore, FOX family members not only have a tight relationship with AR, but 
also represent a pivotal group of proteins to be targeted for PCa therapy. The present review 
focuses primarily on recent advances in the epigenetic, mechanistic and clinical relevant aspects of 
regulation of the AR by FOXA1 and FOXO1 factors in PCa. 
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Introduction 
Prostate cancer (PCa) is one of the most com-
monly diagnosed cancers in men. Increasing evidence 
suggests that its etiology is related to hormones, ge-
netic and epigenetic factors and lifestyle patterns [1]. 
The androgen receptor (AR) is a nuclear hormone 
receptor that is activated by binding to androgenic 
hormones, such as testosterone and dihydrotestos-
terone (DHT), in the cytoplasm and translocation into 
the nucleus  [2, 3]. AR binds to androgen via  its 
COOH-terminal ligand binding domain (LBD). The 
NH2-terminal of AR contains the transcriptional ac-
tivation domain, and this activity is modified by a 
number of cofactors [4]. Androgens, via the AR, are 
essential for the growth and survival of andro-
gen-dependent PCa cells  [5]. Androgen ablation 
therapies, which involve surgical or chemical castra-
tion and/or androgen antagonists, have been the 
mainstay of treatment for advanced andro-
gen-dependent PCa since 1941 [6, 7]. However, cas-
tration-resistant prostate cancer (CRPC) is a major 
challenge for PCa therapy in the clinic. In virtually all 
cases, castration-resistant progression is accompanied 
by resurgence of prostate-specific antigen (PSA), a ca-
nonical AR target gene, indicating that the AR is per-
sistently activated in CRPC. A number of mechanisms 
underlying AR reactivation under castration condi-
tions have been demonstrated.  These include in-
creased AR expression, AR mutation in the LBD, in-
tratumoral (intracrine) synthesis of androgens from 
inactive precursors, alterations in AR coactivators and 
expression of constitutively active AR splice variants 
[8-14].  Here, we review recent findings regarding 
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mechanisms by which the function of AR is modu-
lated by forkhead factors, particularly, FOXA1 and 
FOXO1 in PCa.  
Forkhead box (Fox) transcription factors are a 
superfamily of proteins. Since the identification of the 
fork head gene in Drosophila melanogaster, the founding 
member of this family whose mutation results in the 
development of a forkhead-like appearance [15], more 
than 100 structurally related Fox transcription factors 
have been identified. The defining feature of Fox 
proteins is the forkhead box, which is also known as 
the winged helix DNA binding domain  [16]. This 
domain possesses approximately 100 amino acids 
[16]. The FOX family is divided into 18 subfamilies in 
humans, such as A-class (FOXA) and O-class (FOXO) 
of FOX proteins.  
The FOXA subfamily has three members 
FOXA1, FOXA2, FOXA3.  FOXA1  is also known as 
hepatocyte  nuclear  factor  3α,  HNF-3α.  All of these 
proteins contain a “winged-helix” DNA binding do-
main (or forkhead domain), consisting of three 
α-helices, three β-sheets, and two loops or wings [17]. 
The crystal structure of the forkhead domain suggests 
that FOXA1 binds to the major groove of DNA. 
FOXA1 contacts site-specific DNA with the loops in a 
manner that closely resembles linker histone  [18]. 
FOXA proteins bind to highly compacted or “closed” 
chromatin [19]. The COOH-terminal domain of FOXA 
makes these genomic regions more accessible to other 
transcription factors such as steroid hormone nuclear 
receptors including AR  [20], implying that FOXA 
proteins can behave as pioneer factors, which engage 
early transcriptional regulatory events [21-23]. 
FOXO proteins in humans, which include 
FOXO1 (FKHR), FOXO3 (FKHRL1 or FOXO3a), 
FOXO4 (AFX) and FOXO6, are important transcrip-
tion factors that modulate the expression of genes 
involved in many cellular functions, such as apoptotic 
cell death, cell cycle control, DNA damage repair, 
glucose metabolism, and carcinogenesis[24].  FOXO 
members contain a conserved DNA binding domain 
and bind a consensus DNA binding sequence 
TTGTTTAC at target genes  [25, 26].  Binding of the 
IGF1 receptor (IGF1R) or insulin receptor by their 
ligands leads to activation of the Phosphatidylinositol 
3-kinase (PI3K)/AKT signaling pathway.  Activated 
AKT phosphorylates FOXO proteins at three different 
Ser/Thr residues (T24, S256 and S319)[27]. FOXO1 can 
also be phosphorylated by CDK1 and CDK2 at serine 
249 in vitro and in vivo [28, 29]. The phosphorylated 
FOXO proteins are exported from the nucleus to the 
cytoplasm, sequestered by 14-3-3 chaperone proteins 
in the cytoplasm [30, 31] and become inactive [31].  
Modulation of AR by FOXA1 
FOXA1 is a pioneer factor for the AR-mediated 
transcriptional program  [32-34].  It also influences a 
subset of estrogen receptor (ER) target genes [33, 35, 
36].  FOXA1 plays a critical role in the growth and 
differentiation of a variety of organs, such as prostate, 
breast, lung and bladder [37-39]. FOXA1 is involved 
in AR-mediated transcriptional regulation of prostate 
genes, such as rat probasin and human PSA [40, 41]. 
FOXA1-binding sites are found in close proximity to 
AR binding sites in regulatory regions of these genes. 
The AR and FOXA1 interact through their 
DNA-binding domains [40]. 
FOXA1 is a global mediator of AR action in 
hormone-dependent PCa. High throughput chroma-
tin immunoprecipitation-sequencing (ChIP-seq) has 
delineated the genome-wide binding sites of AR and 
FOXA1 (the AR and FOXA1 cistromes) in parental 
LNCaP-1F5 cells and cells depleted of FOXA1 protein. 
Similar experiments on AR binding were performed 
in VCaP cells [42] (Fig. 1). Approximately 70% of AR 
binding sites are present in  junction with FOXA1 
binding sites genome-wide in LNCaP cells  [43].  Si-
lencing of FOXA1 results in the appearance of over 
13,000 new AR-occupied sites.  Experiments have 
demonstrated that FOXA1 can both assist and antag-
onize AR activity, depending on the cellular context 
[44].  
High-throughput analyses revealed a complex 
relationship between FOXA1, AR and histone mark-
ers [45]. These studies include genome-wide distribu-
tion data of H3K4 di-methylation (H3K4me2), CCCTC 
binding factor (CTCF), AR and FOXA1 DNA binding 
data as well as androgen-regulated gene expression 
profiling data. Notably, FOXA1 functions not only as 
a pioneer factor facilitating AR-mediated gene activa-
tion, but also as a cofactor of AR-mediated gene re-
pression. A new class of AR-FOXA1 regulated genes 
has been identified recently [45]. It was found that in a 
subset of androgen-responsive gene loci, FOXA1 
binding sites are located within the CTCF binding 
sites, which are significantly enriched near the 
AR/H3K4me2 overlapped regions.  Importantly, 
genes enriched in this class are involved in can-
cer-related pathways and are downregulated in met-
astatic PCa in comparison to localized disease. It has 
been proposed that the activated enhancers occupied 
by FOXA1 and AR are defined not only by histone 
markers, but are also related to enhancer-templated 
expression of non-coding RNA (eRNA) in LNCaP 
cells [44]. Thus, eRNAs represent a novel and robust 
indicator of the FOXA1/AR-regulated enhancer in the 
genome.  
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Figure 1. Converging of FOXA1 and AR-regulated pathways in prostate cancer. Left, FOXA1, as a pioneer factor, opens the closed chromatin, and recruits AR to the 
binding region of DNA. As a result, AR regulates expression of its target genes to promote PCa cell growth but inhibits PCa cell metastasis. Right, in CRPC, there are two distinct 
pathways underlying AR regulation of CRPC cell growth. One is that AR itself opens and maintains the chromatin and activates its target genes. The other is that high levels of 
FOXA1 facilitate AR to become sensitive to low levels of androgens. Thus activated AR transactivates its target genes. Both pathways contribute to CRPC cell growth. 
 
FOXA1 can also form a complex with AR and its 
target genes. NKX3.1, AR, and FOXA1 coordinate 
with each other, thereby increasing PCa cell survival 
by directly upregulating RAB3B, a member of the 
RAB GTPase family [46]. RAB3B is overexpressed in 
PCa patient specimens, suggesting that RAB3B to-
gether with AR, FOXA1, and NKX3.1 are important 
for PCa progression. These findings suggest that the 
AR target gene NKX3.1 can coordinate with AR and 
FOXA1 in a feedback manner in androgen-dependent 
PCa[46].  FOXA1 regulates two distinct oncogenic 
processes  via  different mechanisms [48].  FOXA1 
promotes cell growth through the AR pathway. On 
the other hand, FOXA1 inhibits cell motility and epi-
thelial-to-mesenchymal transition (EMT) through an 
AR-independent mechanism [25, 47]. This action di-
rectly opposes the action of AR signaling. FOXA1 has 
a metastasis inhibitory function independently of AR 
in PCa[48] (Fig. 1). 
FOXA1 also modulates AR activity in metastatic 
PCa. High-level nuclear FOXA1 expression is detect-
ed in 19% of primary and 89% of metastatic prostate 
tumors. Increased expression of FOXA1 results in an 
overactive AR complex that is responsive to low levels 
of DHT[49] (Fig. 1). As such, high levels of FOXA1 are 
related to poor prognosis of PCa. Clinical data show 
that FOXA1expression positively correlates with tu-
mor size, extra prostatic extension, angiolymphatic 
invasion, AR levels and lymph node metastases at 
diagnosis, but does not correlate with age, tumor 
stage, Gleason score, prostatic intraepithelial neo-
plasia (PIN) lesions, multifocality, perineural associa-
tion, seminal  vesicle invasion, or surgical excision 
margin status[49]. Importantly, high-level FOXA1 
expression is associated with the development of 
metastatic PCa[49]. Novel recurrent mutations in 
FOXA1 were identified in 5 of 147 (3.4%) prostate 
cancers (both untreated localized PCa and CRPC) [50]. 
Mutated FOXA1 represses androgen/AR signaling, 
and paradoxically enhances tumor growth [50]. 
Although previous studies have focused on lig-
and-dependent AR signaling, a FOXA1-independent 
function of AR activity has been discovered under 
androgen deprived conditions [51], where AR persis-
tently occupies a distinct set of genomic loci following 
androgen deprivation.  These androgen-independent 
AR-occupied regions have constitutively open chro-
matin structures that lack the canonical androgen re-
sponse element and are independent of FOXA1 (Fig. 
1). FOXA1 acts as an AR cofactor in CRPC cells to 
drive the G2-to-M phase cell-cycle transit  [52].  A 
mechanistically different, AR-independent role of 
FOXA1 was shown to drive G1-to-S phase cell-cycle 
transit in CRPC. FOXA1, without AR, interacts with 
MYBL2 or CREB1 on the promoters of Cyclin E2 and 
E2F1. The induced Cyclin E2 and E2F1 drive the Int. J. Biol. Sci. 2014, Vol. 10 
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G1-to-S cell-cycle transition in CRPC. 
Modulation of AR by FOXO Factors 
FOXO1 is deleted in a significant portion of hu-
man PCa cell lines, xenografts and clinical specimens 
[53], suggesting that FOXO1 functions as a tumor 
suppressor in the prostate.  In agreement with this 
concept, FOXO1 inhibits androgen/androgen recep-
tor-mediated gene expression and suppresses PCa cell 
proliferation. These inhibitory effects of FOXO1 on the 
transcriptional activity of AR are attenuated by IGF1 
through the AKT pathway [54]. Interestingly, a posi-
tive feedback circuit working locally in an auto-
crine/intracrine manner has been described. Lig-
and-bound AR up-regulates IGF1 receptor expression 
in PCa cells, presumably resulting in higher IGF1 
signaling output and further enhancing functions of 
the receptor itself through inhibition of FOXO1[54]. 
Notably, there exists another feedback loop. AR can 
bind to the FOXO1 promoter and repress its expres-
sion. Chromodomain helicase DNA-binding protein 1 
(CHD1) is required for efficient recruitment of AR to 
responsive promoters and regulates expression of 
known AR-responsive tumor suppressor genes, in-
cluding FOXO1, NKX3.1, and PPAR γ[55]. 
Mutagenesis analysis revealed that a region in 
FOXO1, from amino acids 150 to 655, which contains 
the forkhead box and COOH-terminal transactivation 
domain, is required for AR inhibition.  Mammalian 
two-hybrid and glutathione-S-transferase pull-down 
assays demonstrated that the inhibition of AR activity 
by FoxO1 involves the interference of andro-
gen-induced interaction of the N- and C-termini of the 
AR and the recruitment of p160 coactivators to the AR 
N-terminus and to the androgen response elements of 
AR target genes[56].  
In addition to inhibiting androgen-dependent 
activation, FOXO1 also inhibits andro-
gen-independent activation of the AR in C4-2 CRPC 
cells [57]. In agreement with this observation, FOXO1 
binds directly to and inhibits the transcriptional ac-
tivity of AR-V7, an AR NH2-terminal splicing variant 
that is constitutively active in the absence of andro-
gens [58]. The transcriptional activity of AR-V7 is in-
hibited by the AKT inhibitors (LY294002, Wortmanin, 
and AKT inhibitor II) in both LNCaP and PC3 PCa cell 
lines.  Mechanistic analyses demonstrated that the 
effect of AKT inhibitors is mediated by the 
PI3K-AKT-FOXO1 signaling axis.  Accordingly, the 
constitutive activity of AR-V7 is largely reduced un-
der conditions of PTEN reactivation.  
The transcription activation unit 5 (TAU5) motif 
in the AR NH2-terminal domain (NTD) interacts with 
AR coactivators such as the p160 family protein 
SRC-1[59]. The TAU5 motif is important for androgen 
independent activation of the AR [60]. FOXO1 binds 
directly to TAU5 and inhibits the constitutive activa-
tion of AR splice variants including AR-V2, V4, V5 
and V7 [61]. While expression of SRC-1 enhances the 
transcriptional activity of AR variants, FOXO1 inhib-
its the SRC-1-induced increase in AR variant tran-
scriptional activity by competing with the binding of 
SRC-1 to the TAU5 motif in the NTD [61]. Important-
ly, AR variants-mediated expression of endogenous 
AR target genes is also inhibited by endogenous 
FOXO1 in 22Rv1 cells [61]. Based upon these findings, 
we envisage a model whereby activation of PTEN 
results in inactivation of AKT, thereby promoting the 
localization of FOXO1 in the nucleus, binding to the 
TAU5 motif and inhibiting the androgen-independent 
activation of the full-length AR and AR splice variants 
(Fig. 2). However, loss of PTEN activates AKT, which 
in turn results in nuclear exclusion of FOXO1 and 
abolishes FOXO1-mediated inhibition of AR, thereby 
driving castration-resistant progression of PCa (Fig. 
2).   
 
Figure 2. Inactivation of the 
PTEN/FOXO1 pathway promotes aber-
rant activation of the AR in prostate 
cancer. Left, in PTEN positive PCa cells, AKT 
is inactivated and FOXO1 cannot be phos-
phorylated by AKT. As a result, the unphos-
phorylated FOXO1 remains in the nucleus and 
binds directly to the TAU5 domain of AR, 
thereby inhibiting androgen-dependent and 
independent activation of the AR. Right, in 
PTEN-inactivated PCa cells, activation of AKT 
leads to FOXO1 phosphorylation and nuclear 
exclusion, which permits the interaction of AR 
with coactivators including p160 family proteins 
such as p160 and p300, thereby favoring 
androgen-dependent and independent activa-
tion of the AR in PCa cells. 
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Taxol chemotherapy is often used to treat CRPC 
patients. Paclitaxel treatment of 22Rv1 CRPC cells 
induces nuclear accumulation of FOXO1, increases 
the association of FOXO1 with AR proteins in the nu-
cleus, and decreases expression of AR target genes 
including PSA, NKX3.1 and TMPRSS2[62]. Increased 
levels of FOXO1 proteins are detected in the promoter 
of the PSA gene in cells treated with paclitaxel. Fur-
thermore, FOXO1 knockdown with small interfering 
RNA attenuates the inhibitory effect of paclitaxel on 
AR transcriptional activity, expression of PSA and 
NKX3.1, and cell survival  [62].  Paclitaxel treatment 
induces increased expression and nuclear localization 
of FOXO1 in 22Rv1 CRPC cells, similar to that ob-
served in breast and ovarian cancer cells [63-65]. Im-
portantly, Taxol-induced inhibition of the AR is me-
diated by the nuclear factor FOXO1  [62].  Tax-
ol-induced inhibition of the AR also suggests a con-
nection between the microtubule-dependent traffick-
ing of the AR and the clinical efficacy of Taxol[66]. 
Other members of the FOXO subfamily, such as 
FOXO3, can also modulate AR expression in an 
indirect manner in PCa cells. It has been hypothesized 
that AKT phosphorylation of FOXO3 is inhibited by 
isoflavone, thereby affecting the down-regulation of 
both AR and its target gene PSA [67]. It was demon-
strated that isoflavone blocks FOXO3 binding to the 
promoter of AR but increases FOXO3a binding to the 
p27KIP1 promoter [67]. This mechanism alters p27KIP1 
and AR expression, inhibits cell proliferation, and 
induces cell apoptosis in both androgen-sensitive and 
-insensitive PCa cells [67]. FOXO3 can induce AR ex-
pression at both the protein and mRNA levels. 
FOXO3 can induce AR promoter activity via binding 
to the AR promoter region from 1290 to 1297 
(5’-TTGTTTCA-3’). Under normal growth conditions, 
blocking PI3K/AKT signals by LY294002 (PI3K in-
hibitor) causes LNCaP cell cycle arrest in G1 phase 
rather than apoptosis [68, 69]. 
Perspectives and Conclusion 
Taken together, these findings suggest that in-
creased FOXA1 results in an overactive AR complex, 
which is responsive to low levels of DHT in CRPC. As 
such, high levels FOXA1 are related to poor prognosis 
of PCa.  On the other hand, AR also has a 
FOXA1-independent function to open and maintain 
chromatin structure. Thus, these AR bound DNA re-
gions do not require FOXA1 for relaxing the chroma-
tin. Apart from FOXA1, FOXO1 blocks AR activity via 
both direct and indirect mechanisms in PCa. FOXO1 
can bind to AR and affect its transcriptional activity. 
FOXO1 can mediate the signaling that controls the 
activity of AR in PCa. However, FOXO3 upregulates 
AR expression via  binding to the promoter of AR. 
Therefore, FOXO factors and AR serve as important 
links between metabolism, the PTEN/AKT pathway 
and nuclear receptor activation in PCa. Targeting the 
FOXA and FOXO factors with drugs may offer selec-
tive means of affecting AR activity in CRPC patients. 
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